83 related articles for article (PubMed ID: 579188)
1. Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
J Natl Cancer Inst; 1977 Dec; 59(6):1619-20. PubMed ID: 579188
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
3. Phase II trial of cytembena in patients with advanced ovarian and breast cancer.
Falkson HC; Falkson G
Cancer Treat Rep; 1976 Nov; 60(11):1655-8. PubMed ID: 1037286
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cytostatic activities of cytembena and cyclophosphamide during short-term administration to women with gynaecological carcinoma.
Skoda V; Jandová A; Novotná J
Neoplasma; 1970; 17(2):175-81. PubMed ID: 5269150
[No Abstract] [Full Text] [Related]
5. Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas.
Baker LH; Samson MK; Izbicki RM
Cancer Treat Rep; 1976 Sep; 60(9):1389-91. PubMed ID: 189923
[No Abstract] [Full Text] [Related]
6. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
7. [Cytoval therapy in advanced ovarian neoplasms].
Tatra G; Breitenecker G
Osterr Z Onkol; 1974; (3-4):66-70. PubMed ID: 4480681
[No Abstract] [Full Text] [Related]
8. A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
Smith DB; Lind MJ; Kaye SB; Newlands ES; Blackledge GR; Gibson A
Br J Cancer; 1988 May; 57(5):512-3. PubMed ID: 3395557
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of cytembena (NSC-104801) in advanced colorectal carcinoma.
Moertel CG; Schutt AJ; Hahn RG; Marciniak TA; Reitemeier RJ
Cancer Chemother Rep; 1975; 59(3):581-3. PubMed ID: 1243107
[No Abstract] [Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of taxol.
Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
12. Cis-dichlorodiammine platinum (II) in advanced ovarian carcinoma.
Stewart JF; Tattersall MH; Woods RL; Fox RM
Med J Aust; 1979 Jun; 1(12):548-50. PubMed ID: 470725
[TBL] [Abstract][Full Text] [Related]
13. A phase II clinical trial of cytembena. Clinical screening group of E.O.R.T.C.
Biomedicine; 1977 Dec; 26(6):392-5. PubMed ID: 342004
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of iproplatin in advanced ovarian carcinoma.
Sessa C; Vermorken J; Renard J; Kaye S; Smith D; ten Bokkel Huinink W; Cavalli F; Pinedo H
J Clin Oncol; 1988 Jan; 6(1):98-105. PubMed ID: 3335895
[TBL] [Abstract][Full Text] [Related]
15. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
De Lena M; Lorusso V; Romito S
Cancer Treat Rep; 1986 Jul; 70(7):893-5. PubMed ID: 3719581
[TBL] [Abstract][Full Text] [Related]
17. [Experiences with cisplatin (Platidiam) chemotherapy in secondary resistant ovarian carcinomas].
Krafft W; Mechl Z; Behling H; Brückmann D; Preibsch W; Kademann J; Schirmer A
Zentralbl Gynakol; 1984; 106(3):175-83. PubMed ID: 6538371
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.
Wiltshaw E; Kroner T
Cancer Treat Rep; 1976 Jan; 60(1):55-60. PubMed ID: 1000519
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
Cancer Treat Rep; 1976 May; 60(5):633-5. PubMed ID: 1036468
[No Abstract] [Full Text] [Related]
20. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
Caponigro F; Willemse P; Sorio R; Floquet A; van Belle S; Demol J; Tambaro R; Comandini A; Capriati A; Adank S; Wanders J
Invest New Drugs; 2005 Jan; 23(1):85-9. PubMed ID: 15528985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
